Rituximab biosimilar for the treatment of diffuse large B-cell lymphoma: a phase 3 randomized study in India

PURPOSE: Very few studies have demonstrated the rituximab biosimilarity in terms of efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity in patients with diffuse large B-cell lymphoma (DLBCL) in India. Therefore, we compared the efficacy, safety, pharmacokinetic, pharmacodynamic,...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Ankit, Bhatt, Niraj, Prakash, S. S., Biswas, Ghanashyam, Nagarkar, Rajnish, Roy, Bodhisatta, Samal, Priyanka, Agrawal, Narendra, Meshram, Sushil, Kaushal, Ashish, Satheesh, C. T., Wategaonkar, Ravikumar, Thiagarajan, Kasi Viswanathan, Jain, Kartikeya, Vijayaveeran, P., Mukherjee , Kalyan, Singh, Kishore, Patil, Tushar, Jain, Amit, Dolai, Tuphan Kanti, Jain, Minish, Hingmire, Sachin, Gupta, Tara Chand, Lakshmaiah, K. C., Rajamanickam, Deepan, Nemade, Bhushan, Goyal, Vikash, Mahato, Pinaki, Mendiratta, Sanjeev Kumar, Doshi, Maulik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124690/
https://www.ncbi.nlm.nih.gov/pubmed/37093266
http://dx.doi.org/10.1007/s00280-023-04530-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124690/
https://www.ncbi.nlm.nih.gov/pubmed/37093266
http://dx.doi.org/10.1007/s00280-023-04530-x

Ejemplares similares